Aktuellt
SENASTE
We make limited estimate revisions after Q3. While Bactiguard is making y/y sales progress, we think there is more to it, especially in the BIP product segment. Bactiguard’s substantial opex growth in recent years (into e.g. product development and marketing activities/go-to-market organisation) has been made to sharply lift product sales – in combination with lucrative licence agreements in place, we see the potential for strong growth ahead.
LÄS MER
